Research programme: Botulinum toxin vaccine - Molecular Targeting Technologies
Latest Information Update: 19 Oct 2015
At a glance
- Originator Molecular Targeting Technologies
- Class Antitoxins; Immunoglobulins
- Mechanism of Action Botulinum toxin inhibitors; Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Botulism
Most Recent Events
- 19 Oct 2015 Preclinical trials in Botulism (Prevention) in USA (Parenteral)